Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 26 to 50 of 60

TitleReference numberPublishedLast updated
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal)TA635
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancerTA628
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancerTA595
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinibTA571
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancerTA529
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pemetrexed for the maintenance treatment of non-small-cell lung cancerTA190
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA444
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapyTA374

Results per page

  1. 10
  2. 25
  3. 50
  4. All